BG
SMMT icon

Bellevue Group’s Summit Therapeutics SMMT Stock Holding History

Bellevue Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$219K – 173
2024
Q3 		$219K Buy
+10,000
New +$140K ﹤0.01% 146

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bellevue Group's SMMT Position: Q1 2026 in Review

Bellevue Group increased its Summit Therapeutics (SMMT) stake by 11% in Q1 2026, buying an estimated $25.8K and bringing the position to 15,858 shares worth $301K. The position accounts for 0.01% of the portfolio, ranked #124.

Bellevue Group first reported a position in SMMT in Q3 2024 and has held it in 7 quarters since. The position peaked at $3.04M in Q4 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Bellevue Group held 15,858 shares of Summit Therapeutics worth $301K as of Q1 2026.
  • Bellevue Group bought 1,596 Summit Therapeutics shares in Q1 2026, an estimated $25.8K.
  • Summit Therapeutics made up 0.01% of Bellevue Group's portfolio in Q1 2026, its #124 holding.
  • Bellevue Group first reported a position in Summit Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Bellevue Group's Summit Therapeutics position peaked at $3.04M in Q4 2024.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.